{"url_path":"/sec/goss/8-k/2026-07-15/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000061-index.html","accession_number":"0001728117-26-000061","cik":"0001728117","ticker":"GOSS","issuer_name":"Gossamer Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1728117/0001728117-26-000061-index.html","primary_entity_key":"0001728117","primary_entity_name":"Gossamer Bio, Inc."},"word_count":248,"has_tables":true,"body_markdown":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nThe Board of Directors of Gossamer Bio, Inc. (the “Company”) previously approved, effective as of May 18, 2026, subject to stockholder approval and the occurrence of the closing date of the Company’s offer to exchange (the “Exchange Offer”) its outstanding $200.0 million in aggregate principal amount of 5.00% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”), an amendment and restatement of the Gossamer Bio, Inc. 2019 Incentive Award Plan (the “Restated Plan”). On July 14, 2026, the Company’s stockholders approved the Restated Plan at the Company’s special meeting of stockholders held on July 14, 2026 (the “Special Meeting”), as further described below. The closing date of the Exchange Offer occurred on June 4, 2026 upon early settlement of the Exchange Offer, as no additional Existing Convertible Notes were validly tendered in the Exchange Offer thereafter. As more fully described in the Company’s “Proxy Statement for Special Meeting of Stockholders” filed on June 9, 2026 (the “Proxy Statement”), the Restated Plan increases the number of shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), authorized for issuance thereunder.\n\nThe foregoing description of the Restated Plan is not complete and is subject to, and qualified in its entirety by, the complete text of the Restated Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and incorporated herein by reference."}